JP2001523443A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001523443A5 JP2001523443A5 JP2000520799A JP2000520799A JP2001523443A5 JP 2001523443 A5 JP2001523443 A5 JP 2001523443A5 JP 2000520799 A JP2000520799 A JP 2000520799A JP 2000520799 A JP2000520799 A JP 2000520799A JP 2001523443 A5 JP2001523443 A5 JP 2001523443A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- production
- tgf
- sle
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 22
- 239000000203 mixture Substances 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 8
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 8
- 210000000822 natural killer cell Anatomy 0.000 description 7
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 6
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000023750 transforming growth factor beta production Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010084313 CD58 Antigens Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- -1 autoantibodies Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 230000032476 lymphotoxin A production Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000009290 primary effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6450797P | 1997-11-05 | 1997-11-05 | |
| US60/064,507 | 1997-11-05 | ||
| PCT/US1998/023584 WO1999025366A1 (en) | 1997-11-05 | 1998-11-05 | Use of cytokines and mitogens to inhibit pathological immune responses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001523443A JP2001523443A (ja) | 2001-11-27 |
| JP2001523443A5 true JP2001523443A5 (https=) | 2006-01-12 |
| JP4309047B2 JP4309047B2 (ja) | 2009-08-05 |
Family
ID=22056456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000520799A Expired - Fee Related JP4309047B2 (ja) | 1997-11-05 | 1998-11-05 | 病的免疫応答を抑制するサイトカインおよびマイトジェンの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6228359B1 (https=) |
| EP (1) | EP1028738B1 (https=) |
| JP (1) | JP4309047B2 (https=) |
| AT (1) | ATE238061T1 (https=) |
| AU (1) | AU747767B2 (https=) |
| CA (1) | CA2309115C (https=) |
| DE (1) | DE69813868T2 (https=) |
| DK (1) | DK1028738T3 (https=) |
| ES (1) | ES2198774T3 (https=) |
| PT (1) | PT1028738E (https=) |
| WO (1) | WO1999025366A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6358506B1 (en) * | 1997-11-05 | 2002-03-19 | University Of Southern California | Use of cytokines and mitogens to inhibit pathological immune responses |
| US20030157057A1 (en) * | 1999-05-05 | 2003-08-21 | Horwitz David A. | Methods for the induction of professional and cytokine-producing regulatory T cells |
| US6803036B1 (en) | 1998-03-03 | 2004-10-12 | University Of Southern California | Use of cytokines, cells and mitogens to inhibit graft versus host disease |
| WO1999048524A1 (en) | 1998-03-03 | 1999-09-30 | University Of Southern California | Use of cytokines and mitogens to inhibit graft versus host disease |
| WO2000066158A2 (en) * | 1999-05-05 | 2000-11-09 | University Of Southern California | Use of cytokines and mitogens to inhibit pathological immune responses |
| DE60042210D1 (de) * | 1999-09-01 | 2009-06-25 | Univ Southern California | Verwendung von cytokinen, zellen und mitogene zur hemmung der graft-versus-host krankheit |
| AU2007202534B2 (en) * | 2000-04-11 | 2011-06-09 | University Of Southern California | A method to prevent graft rejection using TGF-beta to induce T suppressor cells |
| AU2001253400B2 (en) * | 2000-04-11 | 2007-03-01 | University Of Southern California | A method to prevent graft rejection using tgf-beta to induce t suppressor cells |
| AU2002364230B2 (en) * | 2001-12-21 | 2008-05-01 | University Of Southern California | Methods for the induction of professional and cytokine-producing regulatory cells |
| US20050202010A1 (en) * | 2003-08-29 | 2005-09-15 | Giroir Brett P. | Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor |
| CN108467852A (zh) | 2010-04-22 | 2018-08-31 | 南加州大学 | 用于扩增和稳定天然调节性t细胞的方法和组合物 |
| WO2013050529A2 (en) | 2011-10-06 | 2013-04-11 | European Molecular Biology Laboratory | Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases |
| US9958456B2 (en) | 2011-10-07 | 2018-05-01 | Baxalta Incorporated | OxMIF as a diagnostic marker |
| US20150110738A1 (en) | 2012-05-04 | 2015-04-23 | University Of Southern California | Methods and compositions for generating and using allogeneic suppressor cells |
| GB201421716D0 (en) * | 2014-12-05 | 2015-01-21 | King S College London | Cell expansion procedure |
-
1998
- 1998-11-05 AU AU13827/99A patent/AU747767B2/en not_active Ceased
- 1998-11-05 WO PCT/US1998/023584 patent/WO1999025366A1/en not_active Ceased
- 1998-11-05 DE DE69813868T patent/DE69813868T2/de not_active Expired - Lifetime
- 1998-11-05 AT AT98957605T patent/ATE238061T1/de active
- 1998-11-05 DK DK98957605T patent/DK1028738T3/da active
- 1998-11-05 JP JP2000520799A patent/JP4309047B2/ja not_active Expired - Fee Related
- 1998-11-05 EP EP98957605A patent/EP1028738B1/en not_active Expired - Lifetime
- 1998-11-05 CA CA2309115A patent/CA2309115C/en not_active Expired - Fee Related
- 1998-11-05 PT PT98957605T patent/PT1028738E/pt unknown
- 1998-11-05 US US09/186,771 patent/US6228359B1/en not_active Expired - Lifetime
- 1998-11-05 ES ES98957605T patent/ES2198774T3/es not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lu et al. | Alopecia areata: pathogenesis and potential for therapy | |
| Shlomchik | Graft-versus-host disease | |
| Gaga et al. | Eosinophil activation and T lymphocyte infiltration in allergen-induced late phase skin reactions and classical delayed-type hypersensitivity | |
| Chen et al. | Adoptive transfer of human gingiva‐derived mesenchymal stem cells ameliorates collagen‐induced arthritis via suppression of Th1 and Th17 cells and enhancement of regulatory T cell differentiation | |
| Haller et al. | Autologous umbilical cord blood infusion for type 1 diabetes | |
| Haslett et al. | Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset | |
| Shaw et al. | Cellular origins of co-stimulator (IL2) and its activity in cytotoxic T lymphocyte responses | |
| Cameron et al. | IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function | |
| JP2001523443A5 (https=) | ||
| Webb et al. | Putative role for interleukin‐7 in the maintenance of the recirculating naive CD4+ T‐cell pool | |
| Ma et al. | Anti‐tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution | |
| Tesar et al. | Aging augments IL-17 T-cell alloimmune responses | |
| Zhang et al. | Allospecific CD4+ effector memory T cells do not induce graft-versus-host disease in mice | |
| Lundie et al. | A central role for hepatic conventional dendritic cells in supporting Th2 responses during helminth infection | |
| JP2008174564A (ja) | 病的免疫応答を抑制するサイトカインおよびマイトジェンの使用 | |
| Horwitz et al. | Role of NK cells and TGF-β in the regulation of T-cell-dependent antibody production in health and autoimmune disease | |
| Bayer et al. | Host CD4+ CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCT | |
| LaPorte et al. | Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8+ T cells | |
| Parkman | Is chronic graft versus host disease an autoimmune disease? | |
| Dieli et al. | Impaired contact hypersensitivity to trinitrochlorobenzene in interleukin‐4‐deficient mice | |
| JP4309047B2 (ja) | 病的免疫応答を抑制するサイトカインおよびマイトジェンの使用 | |
| Kawashima-Vasconcelos et al. | Reconstitution of the immune system and clinical correlates after stem cell transplantation for systemic sclerosis | |
| Monte et al. | Increased number and function of FoxP3 regulatory T cells during experimental arthritis | |
| Nagata et al. | Specific immunotherapy reduces the antigen-dependent production of eosinophil chemotactic activity from mononuclear cells in patients with atopic asthma | |
| Meretey et al. | Effect of histamine on the mitogenic response of human lymphocytes and its modification by cimetidine and levamisole |